CIDRAP newsletters options
Most bloodstream infections caused by resistant E coli involve human-associated strains.
According to the World Health Organization's (WHO's) Ebola dashboard today, officials in the Democratic Republic of the Congo (DRC) confirmed 2 new cases of Ebola in a 14-month-long outbreak in that country, raising the total to 3,250 infections.
As reported yesterday, 117 of the cases are considered probable infections. The DRC's Ebola technical committee (CMRE) has not yet posted information on the four new cases described yesterday.
A new study conducted in a 400-bed community hospital in Toronto shows that high-intensity prospective audit and feedback (PAF) was tied to a greater reduction in antimicrobial use than low-intensity interventions. The study appeared yesterday in Infection Control & Hospital Epidemiology.
Also, a study shows that conflict during the outbreak dampened the effectiveness of vaccine efforts.
The study also found that MRSA infections declined in all facilities, perhaps due to other prevention steps.
The World Health Organization (WHO) yesterday published a roadmap for implementing antimicrobial stewardship programs in healthcare facilities in low- and middle-income countries (LMICs).
The US Centers for Disease Control and Prevention (CDC) announced the launch of a new study to detect and better understand acute febrile illnesses (AFIs) in Belize, Guatemala, and the Dominican Republic.
In other developments, top health officials from 10 African nations met in the DRC today and agreed on a joint preparedness framework.
A new study in Nature Medicine offers the first clear evidence of enterovirus (EV) in the cerebrospinal fluids of patients with acute flaccid myelitis (AFM) – a mysterious, polio-like illness that can cause paralysis in otherwise healthy children.
A study today in Infection Control & Hospital Epidemiology has determined that an electronic best practice advisory combined with prescriber education was associated with reduced antibiotic prescribing for adults with acute bronchitis.
Of 10 million people estimated to have TB in 2018, 7 million were diagnosed, meeting a recent UN goal.
In other Ebola developments today, three newly confirmed cases were reported in the outbreak region.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Originally published by CIDRAP News Oct 17
The Food and Drug Administration (FDA) approved the use single-dose Xofluza (baloxavir marboxil) for patients ages 12 and over who are at high risk for influenza complications. Xofluza should only be administered to patients who have been symptomatic for 48 hours or less.
Coverage for 3 key childhood vaccines remains near 95% but varies by state, the CDC says.
Today the Democratic Republic of the Congo (DRC) confirmed one new case of Ebola in the ongoing outbreak in North Kivu and Ituri provinces, but the World Health Organization (WHO) spotlighted some troubling signs in its weeks update.
In a 14-2 vote, the US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee yesterday recommended that the new antibiotic cefiderocol, made by Shionogi & Co, Ltd, of Japan, be approved for complicated urinary tract infection (cUTI), including pyelonephritis, caused by gram-negative bacteria in patients who have limited or no alternative treatment options available, the company said in a news r
Recent cases have been in a compact area with limited access and security problems.
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee is meeting today to discuss the new drug application (NDA) for cefiderocol, an investigational antibiotic developed by Shionogi, Inc, a US-based subsidiary of Japanese pharmaceutical company Shionogi & Co.
Yesterday three of the nation's biggest health organizations—the American Lung Association, the American Diabetes Association, and the American Heart Association—recommended that Americans living with chronic health conditions get this year's seasonal influenza vaccine.
